Last reviewed · How we verify

Sm29 Protein, Schistosoma Mansoni

Hospital Universitário Professor Edgard Santos · Phase 1 active Small molecule Quality 0/100

Sm29 Protein, Schistosoma Mansoni is a Small molecule drug developed by Hospital Universitário Professor Edgard Santos. It is currently in Phase 1 development. Also known as: Pentavalent antimony (Sbv).

At a glance

Generic nameSm29 Protein, Schistosoma Mansoni
Also known asPentavalent antimony (Sbv)
SponsorHospital Universitário Professor Edgard Santos
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sm29 Protein, Schistosoma Mansoni

What is Sm29 Protein, Schistosoma Mansoni?

Sm29 Protein, Schistosoma Mansoni is a Small molecule drug developed by Hospital Universitário Professor Edgard Santos.

Who makes Sm29 Protein, Schistosoma Mansoni?

Sm29 Protein, Schistosoma Mansoni is developed by Hospital Universitário Professor Edgard Santos (see full Hospital Universitário Professor Edgard Santos pipeline at /company/hospital-universit-rio-professor-edgard-santos).

Is Sm29 Protein, Schistosoma Mansoni also known as anything else?

Sm29 Protein, Schistosoma Mansoni is also known as Pentavalent antimony (Sbv).

What development phase is Sm29 Protein, Schistosoma Mansoni in?

Sm29 Protein, Schistosoma Mansoni is in Phase 1.

Related